Nasopharyngeal Neoplasms
Conditions
Brief summary
This trial plans to enroll 40 patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0) locoregionally-advanced nasopharyngeal carcinoma (NPC). Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation. All patients will receive intensity-modulated radiotherapy (IMRT). Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 6 cycles.
Interventions
DRUGCisplatin
Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
RADIATIONintensity-modulated radiotherapy
Definitive IMRT of 66-70Gy will be given in six to seven weeks.
DRUGSintilimab
Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
DRUGGemcitabine
Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically confirmed nasopharyngeal carcinoma. 2. Tumor staged as III-IVA (AJCC 8th, except T3N0-1 or T4N0). 3. ECOG performance status ≤1. 4. Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L. 5. Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×upper limit of normal (ULN), and bilirubin ≤ 1.5×ULN. 6. Adequate renal function: creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula). 7. Patients must be informed of the investigational nature of this study and give written informed consent. 8. Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug. Men who are sexually active with WOCBP must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug.
Exclusion criteria
1. Age \> 65 or \< 18. 2. Hepatitis B surface antigen (HBsAg) positive and HBV DNA \>1×10e3 copies/ml 3. Hepatitis C virus (HCV) antibody positive 4. Has active autoimmune disease, except type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia). 5. Has a known history of interstitial lung disease. 6. Has any condition that required systemic corticosteroid (equivalent to prednisone \>10mg/d) or other immunosuppressive therapy within 28 days before informed consent. Patients received systemic corticosteroid equivalent to prednisone ≤10mg/d, inhale or topical corticosteroid will be allowed. 7. Has received a live vaccine within 30 days before informed consent or will receive a live vaccine in the near future. 8. Is pregnant or breastfeeding. 9. Prior malignancy within 5 years, except in situ cancer, adequately treated non-melanoma skin cancer, and papillary thyroid carcinoma. 10. Has known allergy to large molecule protein products or any compound of sintilimab. 11. Has a known history of human immunodeficiency virus (HIV) infection. 12. Any other condition, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic therapy, mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immune-related adverse events (irAEs) and serious adverse events (irSAEs) | From the date of informed consent to 100 days after treatment | Graded according to CTCAE V5.0 |
| All adverse events (AEs) and serious adverse events (SAEs) | From the date of informed consent to 100 days after treatment | Graded according to CTCAE V5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Failure-free survival | 3 years | calculated from the date of informed consent to the date of locoregional failure, distant failure, or death from any cause, whichever occurred first. |
| Overall survival | 3 years | calculated from the date of informed consent to the date of death from any cause. |
| The proportion of patients who completed radiation within 8 weeks | 8 weeks | — |
| Locoregional failure-free survival | 3 years | calculated from the date of informed consent to the the date of locoregional persistence or 1st locoregional recurrence. |
| Distant failure-free survival | 3 years | calculated from the date of informed consent to the date of distant metastasis. |
| The proportion of patients who completed 6 cycles of sintilimab | From the date of informed consent to the end of treatment, assessed up to 20 weeks. | — |
Countries
China
Contacts
Primary ContactJun Ma
Outcome results
None listed